Last reviewed · How we verify
Ramelteon (RozeremR)
Ramelteon is a melatonin receptor agonist that binds to MT1 and MT2 receptors in the brain to promote sleep onset and maintain circadian rhythm.
Ramelteon is a melatonin receptor agonist that binds to MT1 and MT2 receptors in the brain to promote sleep onset and maintain circadian rhythm. Used for Insomnia, particularly sleep-onset insomnia.
At a glance
| Generic name | Ramelteon (RozeremR) |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | Melatonin receptor agonist |
| Target | MT1 and MT2 melatonin receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Ramelteon selectively targets melatonin receptors MT1 and MT2 located in the suprachiasmatic nucleus, the brain's master circadian clock. By activating these receptors, it helps synchronize the sleep-wake cycle and promotes sleep initiation without the sedative properties of traditional hypnotics. This mechanism makes it particularly useful for circadian rhythm sleep disorders.
Approved indications
- Insomnia, particularly sleep-onset insomnia
Common side effects
- Dizziness
- Fatigue
- Headache
- Nausea
- Somnolence
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramelteon (RozeremR) CI brief — competitive landscape report
- Ramelteon (RozeremR) updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI